ReviewLeukemia2013
Personalized management of essential thrombocythemia-application of recent evidence to clinical practice.
Review in Leukemia, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 56 citations in OpenAlex.
- Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia.Cardiovascular toxicology · 2021Trial
- Trial
- JAK2 V617F, MPL, and CALR mutations in essential thrombocythaemia and major thrombotic complications: a single-institute retrospective analysis.Pathology oncology research : POR · 2015Trial
- The importance of cardiovascular risk factors for thrombosis prediction in patients with essential thrombocythemia.Medical oncology (Northwood, London, England) · 2014Trial
- Prefibrotic myelofibrosis: recent updates in diagnosis, prognostication, and management 2026.Therapeutic advances in hematology · 2026Review
- Practical management of the haemorrhagic complications of myeloproliferative neoplasms.British journal of haematology · 2022Review
- The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms.European heart journal · 2021Article
- Hematological Malignancies and Arterial Thromboembolism.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2019Review
- Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper.Blood cancer journal · 2019Article
- Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis.Current hematologic malignancy reports · 2017Review
- [Chinese expert consensus on the diagnosis and treatment of essential thrombcythaemia(2016)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016Article
- Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera.Anatolian journal of cardiology · 2016Article
- Recent advances in understanding myelofibrosis and essential thrombocythemia.F1000Research · 2016Review
- Advances and challenges in the management of essential thrombocythemia.Therapeutic advances in hematology · 2015Review
- Thrombotic risk assessment in 185 WHO-defined essential thrombocythemia patients: single center experience.Contemporary oncology (Poznan, Poland) · 2015Article
- Melanonychia Secondary to Long-Term Treatment with Hydroxycarbamide: An Essential Thrombocytosis Case.Case reports in hematology · 2015Article
- Antiplatelet therapy in the management of myeloproliferative neoplasms.Current hematologic malignancy reports · 2014Review
- An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.Leukemia · 2014Review
- Are MPNs vascular diseases?Current hematologic malignancy reports · 2013Review
- Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.Leukemia · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The World Health Organization (WHO) classification system has recently strengthened the diagnostic criteria for essential thrombocythemia (ET) by lowering the threshold platelet count, underscoring its morphological distinction from early/prefibrotic myelofibrosis (MF) and incorporating molecular markers of clonality. The International Working Group for Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) examined the clinical relevance of this process in 1104 cases of locally diagnosed 'ET' and showed worse overall, leukemia-free and fibrosis-free survival, and a higher risk of bleeding in early/prefibrotic MF (n=180) vs WHO-defined ET (n=891). The risk of thrombosis was similar between the two entities and, in WHO-defined ET, was predicted by thrombosis history, older age, cardiovascular risk factors and JAK2V617F. A prognostic model based on these risk factors identified patient groups in ET with residual risk of thrombosis, despite treatment with conventional therapy. The main objectives of the current perspective are to underscore the prognostic importance of morphological confirmation in the diagnosis of ET and provide management recommendations, in both WHO-defined ET and early/prefibrotic MF, based on observations from the aforementioned IWG-MRT and other studies. In so doing, we are fully cognizant and sympathetic of the fact that some of our recommendations need to be tested in prospective controlled studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.